Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-8 of  8 results for ""Canagliflozin""

Your Filters

Publisher : sage publications Subject : biomarkers Subject : diabetes mellitus, type 2 Subject : glucose intolerance Subject : sex characteristics
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Canagliflozin and Amputation Risk: Evidence So Far.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetic Foot*/Diabetic Foot*/Diabetic Foot*/etiology

  • Source: The international journal of lower extremity wounds [Int J Low Extrem Wounds] 2020 Mar; Vol. 19 (1), pp. 21-26. Date of Electronic Publication: 2019 Nov 08.Publisher: Sage Publications Country of Publication: United States NLM ID: 101128359 Publication Model: Print-Electronic

Record details

Read More Add to Saved list
×
Academic Journal

Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.

  • Authors : Takashima H; Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.; Yoshida Y

Subjects: Sodium-Glucose Transporter 2 Inhibitors*; Blood Glucose/Blood Glucose/Blood Glucose/*drug effects ; Canagliflozin/Canagliflozin/Canagliflozin/*therapeutic use

  • Source: Diabetes & vascular disease research [Diab Vasc Dis Res] 2018 Sep; Vol. 15 (5), pp. 469-472. Date of Electronic Publication: 2018 Jun 20.Publisher: Sage Publications Country of Publication: England NLM ID: 101234011 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy.

  • Authors : Takenaka T; 1 Department of Medicine, International University of Health and Welfare, Clinical Research Center, Sanno Hospital, Tokyo, Japan.; Kishimoto M

Subjects: Sodium-Glucose Transporter 2 Inhibitors*; Blood Pressure/Blood Pressure/Blood Pressure/*drug effects ; Canagliflozin/Canagliflozin/Canagliflozin/*therapeutic use

  • Source: Diabetes & vascular disease research [Diab Vasc Dis Res] 2017 May; Vol. 14 (3), pp. 258-261. Date of Electronic Publication: 2017 Feb 01.Publisher: Sage Publications Country of Publication: England NLM ID: 101234011 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review.

  • Authors : Skeik N; Vascular Medicine, Thrombophilia and Anticoagulation Clinic, Vein Center, and Vascular Laboratories, Allina Health Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, USA.; Elejla SA

Subjects: Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/diagnosis ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/drug therapy ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/prevention & control

  • Source: Vascular medicine (London, England) [Vasc Med] 2023 Feb; Vol. 28 (1), pp. 62-76. Date of Electronic Publication: 2023 Jan 02.Publisher: SAGE Publications Country of Publication: England NLM ID: 9610930 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Relationship of concomitant anti-diabetic drug administration with sodium-glucose co-transporter 2 inhibitor-related ketosis.

  • Authors : Lin CW; Division of Endocrinology and Metabolism, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan.; Hung SY

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Ketosis*/Ketosis*/Ketosis*/chemically induced

  • Source: The Journal of international medical research [J Int Med Res] 2022 Mar; Vol. 50 (3), pp. 3000605221090095.Publisher: Sage Publications Country of Publication: England NLM ID: 0346411 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.

  • Authors : Qiu M; Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China.; Ding LL

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Heart Failure/Heart Failure/Heart Failure/*drug therapy ; Renal Insufficiency, Chronic/Renal Insufficiency, Chronic/Renal Insufficiency, Chronic/*drug therapy

  • Source: Diabetes & vascular disease research [Diab Vasc Dis Res] 2021 Mar-Apr; Vol. 18 (2), pp. 14791641211011016.Publisher: Sage Publications Country of Publication: England NLM ID: 101234011 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction.

  • Authors : Genuardi MV; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Mather PJ

Subjects: Blood Glucose/Blood Glucose/Blood Glucose/*drug effects ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Heart Failure/Heart Failure/Heart Failure/*drug therapy

  • Source: Therapeutic advances in cardiovascular disease [Ther Adv Cardiovasc Dis] 2021 Jan-Dec; Vol. 15, pp. 17539447211002678.Publisher: Sage Publications Country of Publication: England NLM ID: 101316343 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.

  • Authors : Yoshimoto T; Department of Endocrinology and Metabolism, Faculty of Medicine, Kagawa University, Miki - cho, Kagawa, Japan.; Furuki T

Subjects: Sodium-Glucose Transporter 2 Inhibitors*; Angiotensinogen/Angiotensinogen/Angiotensinogen/*urine ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*urine

  • Source: Journal of investigative medicine : the official publication of the American Federation for Clinical Research [J Investig Med] 2017 Oct; Vol. 65 (7), pp. 1057-1061. Date of Electronic Publisher: SAGE Publications Country of Publication: England NLM ID: 9501229 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
  • 1-8 of  8 results for ""Canagliflozin""